Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Papillomavirus Infections 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1COVID-19 1

Interventions

pembrolizumab 223Carboplatin 219Cisplatin 206Paclitaxel 182Gemcitabine 149Docetaxel 127Capecitabine 115Pemetrexed 102Dexamethasone 102Cyclophosphamide 102Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 96Radiotherapy 95Doxorubicin 92Fluorouracil 88Bevacizumab 84Nivolumab 74Leucovorin 73Rituximab 71Vincristine 68durvalumab 66Lenalidomide 64Radiation 62Etoposide 62atezolizumab 61Irinotecan 61130-nm albumin-bound paclitaxel 58Prednisone 57Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × 2019-nCoV Vaccine mRNA-1273 × 1 year × Clear all
NCT05119855 2026-02-05

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Merck Sharp & Dohme LLC

Phase 3 Completed
165 enrolled 13 charts

COVID-19, Papillomavirus Infections

NCT05556720 2025-10-03

BOOST-IC

Monash University

Phase 3 Active not recruiting
960 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡